Molecular Formula | C18H17NO4 |
Molar Mass | 311.335 |
Melting Point | 214 °C |
Solubility | DMSO: 18mg/mL soluble |
Appearance | solid |
Color | yellow |
Storage Condition | protect from light |
In vitro study | Treatment with IC261 resulted in p53-dependent cell cycle arrest, leaving the DNA content at 4N. Its effects on cell cycle progression, like those of other spindle inhibitors, will depend on the state of p53 in the cell. |
In vivo study | Intrathecal injection of the CK1 inhibitor IC261 slows the behavior of neuropathic pain. CK1 inhibitors were effective in reducing spinal stimulant responses to presynaptic electrical stimulation in neurogenic mice. Targeting CK1 by IC261 affects pancreatic tumor cell growth in vitro and sensitivity to apoptosis, affecting tumor growth in vivo. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.212 ml | 16.06 ml | 32.12 ml |
5 mM | 0.642 ml | 3.212 ml | 6.424 ml |
10 mM | 0.321 ml | 1.606 ml | 3.212 ml |
5 mM | 0.064 ml | 0.321 ml | 0.642 ml |
biological activity | IC261 (SU-5607) is a novel CK1 inhibitor, the IC50 of IC261 for CK1 was 16 μm and for Cdk5 was 4.5 mM. |
Target | Value |
CK1 () | 16 μM |